Illumina Inc. (ILMN) Downgraded to Hold at Vetr Inc.
Illumina Inc. (NASDAQ:ILMN) was downgraded by Vetr from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday. They currently have a $187.86 target price on the life sciences company’s stock. Vetr‘s price objective would indicate a potential upside of 1.63% from the company’s previous close.
Other equities analysts have also issued research reports about the company. CL King initiated coverage on Illumina in a research report on Tuesday, June 21st. They issued a “buy” rating and a $165.00 price target for the company. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $190.00 price target for the company in a research report on Friday, August 26th. Argus increased their price target on Illumina from $175.00 to $185.00 and gave the company a “buy” rating in a research report on Monday, August 8th. Citigroup Inc. increased their price target on Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, September 12th. Finally, Cantor Fitzgerald restated a “hold” rating and set a $165.00 price objective on shares of Illumina in a research report on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, sixteen have given a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $165.56.
Shares of Illumina (NASDAQ:ILMN) traded up 0.20% on Monday, hitting $184.85. 1,889,978 shares of the stock traded hands. Illumina has a one year low of $127.10 and a one year high of $196.47. The stock has a 50 day moving average of $175.01 and a 200 day moving average of $156.56. The company has a market cap of $27.10 billion, a PE ratio of 63.30 and a beta of 0.47.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/illumina-inc-ilmn-downgraded-to-hold-at-vetr-inc.html
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.13. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The business earned $600 million during the quarter, compared to analyst estimates of $31.91 million. During the same quarter last year, the company posted $0.80 EPS. Illumina’s revenue for the quarter was up 11.3% on a year-over-year basis. Equities analysts anticipate that Illumina will post $3.53 earnings per share for the current year.
In other Illumina news, Director Jay T. Flatley sold 10,000 shares of the business’s stock in a transaction on Monday, July 18th. The stock was sold at an average price of $150.00, for a total value of $1,500,000.00. Following the transaction, the director now owns 498,061 shares of the company’s stock, valued at $74,709,150. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director A Blaine Bowman sold 5,000 shares of the business’s stock in a transaction on Thursday, July 14th. The stock was sold at an average price of $147.14, for a total value of $735,700.00. Following the completion of the transaction, the director now directly owns 20,704 shares in the company, valued at approximately $3,046,386.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Physicians Financial Services Inc. raised its position in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new position in Illumina during the second quarter worth approximately $112,000. Ropes Wealth Advisors LLC raised its position in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares in the last quarter. Finally, Checchi Capital Advisers LLC raised its position in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares in the last quarter. 95.22% of the stock is currently owned by institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.